| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/22/2002 | EP1206466A1 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| 05/22/2002 | EP1206465A1 Fatty acid synthase inhibitors |
| 05/22/2002 | EP1206464A1 Fatty acid synthase inhibitors |
| 05/22/2002 | EP1206463A1 Fatty acid synthase inhibitors |
| 05/22/2002 | EP1206462A2 Heterocyclic compounds inhibiting angiogenesis |
| 05/22/2002 | EP1206458A1 Benzoxazine and benzothiazine derivatives and the use thereof in medicaments |
| 05/22/2002 | EP1206457A1 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| 05/22/2002 | EP1206455A1 ALPHAvBETA3 INTEGRIN INHIBITORS |
| 05/22/2002 | EP1206454A1 NOVEL INTEGRIN ALPHAvBETA3 INHIBITORS |
| 05/22/2002 | EP1206452A2 Novel method for preparing benzoperhydroisoindole compounds |
| 05/22/2002 | EP1206448A1 Novel vitamin d analogues |
| 05/22/2002 | EP1206447A1 Selective inhibitors of the urokinase plasminogene activators |
| 05/22/2002 | EP1206446A1 Carboxylic acid amides, their production and their use as drugs |
| 05/22/2002 | EP1206444A1 Compounds that inhibit tryptase activity |
| 05/22/2002 | EP1206442A1 Substituted chiral allosteric hemoglobin modifiers |
| 05/22/2002 | EP1206436A2 Retinoids for the treatment of emphysema |
| 05/22/2002 | EP1206429A2 Stilbenes with vascular damaging activity |
| 05/22/2002 | EP1206428A1 Use of hydroxyethers in cosmetic and pharmaceutical preparations |
| 05/22/2002 | EP1206285A2 Drug-carrier complexes and methods of use thereof |
| 05/22/2002 | EP1206284A1 Method for delivery of therapeutic agents using a solution of dextrin |
| 05/22/2002 | EP1206283A2 Improved cellular uptake of bioactive agents |
| 05/22/2002 | EP1206281A1 Moxifloxacin formulation containing common salt |
| 05/22/2002 | EP1206270A1 Ceramide and chemotherapeutic agents for inducing cell death |
| 05/22/2002 | EP1206268A1 Novel compositions for controlled release of a biologically active agent, and the preparation thereof |
| 05/22/2002 | EP1206267A1 Medicaments that contain xenogenic oligo- or/and polyribonucleotides |
| 05/22/2002 | EP1206266A2 Formulations for parenteral use of estramustine phosphate and albumin |
| 05/22/2002 | EP1206265A1 Src kinase inhibitor compounds |
| 05/22/2002 | EP1206264A2 Compositions and methods for treating opiate intolerance |
| 05/22/2002 | EP1206263A1 Ft-raman spectroscopic measurement of omeprazole isomer ratio in a composition |
| 05/22/2002 | EP1206262A1 Npy antagonists: spiroisoquinolinone derivatives |
| 05/22/2002 | EP1206261A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 05/22/2002 | EP1206260A1 Src kinase inhibitor compounds |
| 05/22/2002 | EP1206259A2 Use of substance p antagonists for the treatment of adenocarcinoma |
| 05/22/2002 | EP1206258A1 Compositions containig esthers for treating parasitic infestations of organisms |
| 05/22/2002 | EP1206257A1 Use of amino acids for making medicines for treating to insulin-resistance |
| 05/22/2002 | EP1206256A2 Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| 05/22/2002 | EP1206255A1 COMPOUNDS OBTAINED FROM i SALVIA SPECIES /i HAVING ANTIVIRAL ACTIVITY |
| 05/22/2002 | EP1206254A1 Drug releasing biodegradable fiber implant |
| 05/22/2002 | EP1206253A1 Pharmaceutical preparation containing nanosol |
| 05/22/2002 | EP1206252A1 Amplification of folate-mediated targeting to tumor cells using polymers |
| 05/22/2002 | EP1206251A1 Amplification of folate-mediated targeting to tumor cells using nanoparticles |
| 05/22/2002 | EP1206248A2 Controlled-release sedative-hypnotic compositions and methods related thereto |
| 05/22/2002 | EP1206245A2 Phospholipid gel |
| 05/22/2002 | EP1206244A2 Aqueous pharmaceutical composition containing moxifloxacin or salts thereof |
| 05/22/2002 | EP1206234A2 Methods and compositions for modulating cell proliferation and cell death |
| 05/22/2002 | EP1206233A2 Serine proteases |
| 05/22/2002 | EP1182200A9 Tricyclic fused heterocycle compounds, process for preparing the same and use thereof |
| 05/22/2002 | EP1169326A4 Process for preparing alendronic acid |
| 05/22/2002 | EP1147107A4 Novel angiogenesis inhibitors |
| 05/22/2002 | EP1140733A4 Process and products of purification of anhydrosugar alcohols |
| 05/22/2002 | EP1109558B1 Sustained release ranolazine formulations |
| 05/22/2002 | EP1089722B1 Matrix-type transdermal patch for steroid hormones |
| 05/22/2002 | EP1042334B1 Acyl phosph(on)ate inhibitors of beta-lactamase |
| 05/22/2002 | EP1014940B1 Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
| 05/22/2002 | EP0981648A4 ANTISENSE INHIBITION OF ras GENE WITH CHIMERIC AND ALTERNATING OLIGONUCLEOTIDES |
| 05/22/2002 | EP0966434B1 Aminophenol derivatives and their use in cosmetics |
| 05/22/2002 | EP0902681B1 Inhibition of selectin binding |
| 05/22/2002 | EP0888349B1 Pyrrolopyrimidines and processes for their preparation |
| 05/22/2002 | EP0799034A4 Treatment of movement disorders using large neutral amino acids |
| 05/22/2002 | EP0792110B1 Silicone compositions |
| 05/22/2002 | EP0766676B1 Compounds for inhibiting phosphodiesterase iv |
| 05/22/2002 | EP0745085B1 Texaphyrin metal complexes having improved functionalization |
| 05/22/2002 | EP0729463B1 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
| 05/22/2002 | EP0685463B1 Indolin-2-one derivative |
| 05/22/2002 | EP0681575B1 Process for the preparation of Baccatin III analogs bearing new C2 and C4 functional groups |
| 05/22/2002 | EP0676960B1 Cycloalkyl amine bis-aryl squalene synthase inhibitors |
| 05/22/2002 | EP0606317B1 Saponin-antigen conjugates and the use thereof |
| 05/22/2002 | EP0583360B1 Compositions for the prevention and/or treatment of pathological processes |
| 05/22/2002 | EP0563238B1 Imidazolyl-alkenoic acids |
| 05/22/2002 | EP0519023B1 Folded sheet means |
| 05/22/2002 | CN1350592A Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 05/22/2002 | CN1350543A 14 beta-H-sterols, PHarmaceutical composiutions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments |
| 05/22/2002 | CN1350542A Xylo-LNA analogues |
| 05/22/2002 | CN1350540A Process for preparing amine platinum complexes |
| 05/22/2002 | CN1350539A Imidazo-containing heterocyclic compounds, their compositions and uses |
| 05/22/2002 | CN1350538A Imiadazodiazepine derivative |
| 05/22/2002 | CN1350537A Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 05/22/2002 | CN1350536A 氨基甲酰基四氢吡啶衍生物 Carbamoyl tetrahydropyridine derivative |
| 05/22/2002 | CN1350535A Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof |
| 05/22/2002 | CN1350534A Substituted bicyclic heteroaryl compounds as integrin antagonists |
| 05/22/2002 | CN1350533A New ECE inhibitors, their production and their use |
| 05/22/2002 | CN1350530A 酰胺衍生物 Amide derivatives |
| 05/22/2002 | CN1350528A 4,5,6,7-tetrahydroindazole derivatives as antitumor agents |
| 05/22/2002 | CN1350527A Aminomethylpyrrolidine derivatives having aromatic substituents |
| 05/22/2002 | CN1350524A Quinoline derivatives as inhibitors of MEK enzymes |
| 05/22/2002 | CN1350523A Indoline derivatives as progesterohe antagonists |
| 05/22/2002 | CN1350520A Cell adhesive-inhibiting anti inflammatory and immune-suppressive compounds |
| 05/22/2002 | CN1350519A Reversible aqueous pH Sensitive lipidizing reagents, compositions and methods of use |
| 05/22/2002 | CN1350512A Method of preparing surface-active alcohols and surface-active alcoholic ethers, products obtained by said method and their use |
| 05/22/2002 | CN1350466A A combination of FBPase Inhibitors and insulin sensitizers for the treatment of diabetes |
| 05/22/2002 | CN1350465A Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetiques |
| 05/22/2002 | CN1350464A Docetaxel in combination with rhumab HER2 for the treatment of cancers |
| 05/22/2002 | CN1350463A A Pharmaceutical formulation containing an inhibitor of carboxypeptidase U and a thrombin inhibitor |
| 05/22/2002 | CN1350459A Glycosaminoglycans having an average molecular weight equal to 2400 D suitable for the treatment of senile dementia |
| 05/22/2002 | CN1350458A Protease inhibitors |
| 05/22/2002 | CN1350457A Use of 1,2,4-triazolo [1,5-A] pyrimide in derivatives for treating migraine |
| 05/22/2002 | CN1350456A Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin |
| 05/22/2002 | CN1350455A Use of combination of vitamins for the treatment of pruritus and relating to itching and/or non-infective inflammatory disorders |
| 05/22/2002 | CN1350454A Apomorphine and sildenafil composition |
| 05/22/2002 | CN1350453A Method for treating exercise induced asthma |